<?xml version="1.0"?>
<Articles JournalTitle="Acta Medica Iranica">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>49</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="epublish">
        <Year>2011</Year>
        <Month>09</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Thyroid-Associated Ophthalmopathy in Iranian Patients</title>
    <FirstPage>612</FirstPage>
    <LastPage>618</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Mohsen</FirstName>
        <LastName>Bahmani Kashkouli</LastName>
        <affiliation locale="en_US">Department of Medicine, Eye Research Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Sara</FirstName>
        <LastName>Jam</LastName>
        <affiliation locale="en_US">Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Duman</FirstName>
        <LastName>Sabzvari</LastName>
        <affiliation locale="en_US">Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Nooshin</FirstName>
        <LastName>Ketabi</LastName>
        <affiliation locale="en_US">Department of Medicine, Eye Research Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Shahrzad</FirstName>
        <LastName>Azarinia</LastName>
        <affiliation locale="en_US">Department of Medicine, Eye Research Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>SeyedAhmad</FirstName>
        <LastName>SeyedAlinaghi</LastName>
        <affiliation locale="en_US">Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Alireza</FirstName>
        <LastName>Mofid</LastName>
        <affiliation locale="en_US">Department of Internal Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>09</Month>
        <Day>28</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">We determined the frequency of clinical thyroid ophthalmopathy in Iranian patients. This crosssectional study was performed at the Endocrinology Institute of Tehran University of Medical Sciences. All&#xA0;patients with documented thyroid disorders from September 2003 to July 2005 were recruited. Eye&#xA0;examinations included evaluation of soft tissue changes, measurement of proptosis, lid width, lagophthalmos,&#xA0;evaluation of eye muscle function, and determination of visual acuity. The activity of ophthalmopathy was&#xA0;scored according to the NOSPECS scale. Among 851 visited patients, 303 cases had thyroid eye disease&#xA0;(TED). The nature of the ophthalmopathy breaks down as follows: 53.4% were hypothyroid (9.3%&#xA0;Hashimoto disease), 5.5% euthyroid and 41.1% had Graves&#x2019; disease. The prevalence of TED in males was&#xA0;60% which was nearly 2 times the prevalence of TED in females. There was a significant relationship&#xA0;between presentation of TED and active smoking of the patients (P&lt;0.0001) while no significant relationship&#xA0;with passive smoking was obtained (P=0.181). The most common clinical sign of TED in descending order&#xA0;respectively were proptosis with 63.4%, soft tissue involvement (40.9%), extraocular muscle involvement&#xA0;(22.1%), corneal involvement (12.9%) and optic nerve dysfunction (6.3%). Myasthenia gravis occurred in&#xA0;only 2 patients. In the logistic regression, occurrence of TED was influenced by cardiovascular disease&#xA0;(OR=5.346), Graves&#x2019; disease (OR=47.507), radioiodine therapy (OR=2.590), and anti-thyroid medications&#xA0;(OR=0.650). Thyroid ophtalmopathy (orbitopathy) is a matter of important health concern among patients&#xA0;with thyroid disorder. Since TED occurred with a high prevalence in all thyroid states, a close collaboration&#xA0;between endocrinologists and ophthalmologists along with timely referrals of patients with any eye complaint&#xA0;is deemed necessary. Also smoking was the most important risk factor for developing TED. Therefore, it is&#xA0;advisable to raise awareness and to strongly encourage smokers with thyroid disorders to quit smoking.</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/3805</web_url>
    <pdf_url>https://acta.tums.ac.ir/index.php/acta/article/download/3805/3780</pdf_url>
  </Article>
</Articles>
